Literature DB >> 22291103

Eczema vaccinatum.

Jennifer L Reed1, Dorothy E Scott, Mike Bray.   

Abstract

Eczema vaccinatum (EV) is a complication of smallpox vaccination that can occur in persons with eczema/atopic dermatitis (AD), in which vaccinia virus disseminates to cause an extensive rash and systemic illness. Because persons with eczema are deferred from vaccination, only a single, accidentally transmitted case of EV has been described in the medical literature since military vaccination was resumed in the United States in 2002. To enhance understanding of EV, we review its history during the era of universal vaccination and discuss its relationship to complications in persons with other diseases or injuries of the skin. We then discuss current concepts of the pathophysiology of AD, noting how defective skin barrier function, epidermal hyperplasia, and abnormal immune responses favor the spread of poxviral infection, and identify a number of unanswered questions about EV. We conclude by considering how its occurrence might be minimized in the event of a return to universal vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291103     DOI: 10.1093/cid/cir952

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

2.  Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.

Authors:  Mark K Slifka; Donald Y M Leung; Erika Hammarlund; Hans-Peter Raué; Eric L Simpson; Susan Tofte; Shahana Baig-Lewis; Gloria David; Henry Lynn; Rob Woolson; Tissa Hata; Henry Milgrom; Jon Hanifin
Journal:  J Allergy Clin Immunol       Date:  2013-12-10       Impact factor: 10.793

Review 3.  Cytokine production associated with smallpox vaccine responses.

Authors:  Whitney L Simon; Hannah M Salk; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Why is eczema herpeticum unexpectedly rare?

Authors:  Donald Y M Leung
Journal:  Antiviral Res       Date:  2013-02-22       Impact factor: 5.970

5.  Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections.

Authors:  Evgeny Berdyshev; Elena Goleva; Irina Bronova; Anna Sofia Bronoff; Joanne E Streib; Kathryn A Vang; Brittany N Richers; Patricia Taylor; Lisa Beck; Miguel Villarreal; Keli Johnson; Gloria David; Mark K Slifka; Jon Hanifin; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2022-03-15       Impact factor: 14.290

Review 6.  Vaccinating against monkeypox in the Democratic Republic of the Congo.

Authors:  Brett W Petersen; Joelle Kabamba; Andrea M McCollum; Robert Shongo Lushima; Emile Okitolonda Wemakoy; Jean-Jacques Muyembe Tamfum; Beatrice Nguete; Christine M Hughes; Benjamin P Monroe; Mary G Reynolds
Journal:  Antiviral Res       Date:  2018-11-14       Impact factor: 5.970

Review 7.  Effects of Allergic Sensitization on Antiviral Immunity: Allergen, Virus, and Host Cell Mechanisms.

Authors:  Regina K Rowe; Michelle A Gill
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.919

8.  Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus.

Authors:  Michiko K Oyoshi; Jacqueline Beaupré; Nicholas Venturelli; Christopher N Lewis; Yoichiro Iwakura; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2015-01-30       Impact factor: 10.793

Review 9.  Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.

Authors:  Oriana Simonetti; Giulia Radi; Elisa Molinelli; Giulio Rizzetto; Federico Diotallevi; Annamaria Offidani
Journal:  Hum Vaccin Immunother       Date:  2021-06-25       Impact factor: 4.526

10.  Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Authors:  Jarmila Knitlova; Vera Hajkova; Ludek Voska; Jana Elsterova; Barbora Obrova; Zora Melkova
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.